Predictive Oncology Inc. — Form 10-Q Summary
Identity note: The filing provided is for Predictive Oncology Inc. (Nasdaq: POAI), not Axe Compute Inc. It covers the quarter and six months ended June 30, 2019; the financial statements are unaudited.
Business context and reporting period
The company combines its STREAMWAY infectious-fluid management products with precision oncology and contract research services. On April 4, 2019, it acquired the remaining 75% of Helomics, making Helomics wholly owned. The company changed its name from Precision Therapeutics Inc. to Predictive Oncology Inc. in June 2019.
Financial results and liquidity
- Revenue: Q2 revenue was $286,151, down 20% from $358,586 a year earlier. Six-month revenue was $541,392, down 30% from $770,179. The company sold 14 STREAMWAY units in the first half of 2019, versus 25 in the prior-year period.
- Margins and operating results: Gross margin was approximately 59% for Q2 and 65% for the first half, versus 70% and 71%, respectively, in 2018. Operating loss was $5.10 million for Q2 and $7.44 million for the first half, as general and administrative and operating expenses rose substantially.
- Net income/loss: Q2 net income was $1.47 million, compared with a $2.37 million loss in Q2 2018. The Q2 result included a $6.16 million gain from revaluing the prior Helomics investment and a $1.22 million gain from revaluing cash advances to Helomics; these items materially affected reported earnings. For the first half, the company reported a net loss of $1.83 million, versus a $4.13 million loss in 2018. Basic earnings per share were $0.05 for Q2; first-half loss per share was $0.08.
- Cash flow: Operating cash use was $4.05 million in the first half, compared with $3.11 million in 2018. Investing activities used $581,000; financing activities provided $4.53 million. Cash fell to $69,557 at June 30, 2019, from $162,152 at year-end.
- Balance sheet and liquidity: Current assets were $1.09 million and current liabilities $9.46 million. Total assets were $32.25 million, including $23.79 million of goodwill; total liabilities were $9.96 million. Accounts payable and accrued expenses totaled approximately $4.57 million. The filing states substantial doubt exists about the company’s ability to continue as a going concern, citing cash needs, operating losses, and debt coming due.
- Debt and financing: The filing describes approximately $2.18 million of secured convertible-note principal due September 28, 2019, with repayment including interest and premiums estimated at approximately $2.88 million, plus $1.895 million of promissory-note principal due in February 2020. It also reports $3.81 million of current notes payable net of discounts on the balance sheet. The company raised $776,000 net from Series E preferred stock in Q2 and reported another $1.24 million net after quarter-end; CEO advances also provided funding.
Material changes versus the prior period
- Helomics’ results were consolidated only from April 4, 2019; acquisition-related assets, liabilities, expenses, and financing make comparisons with 2018 less directly comparable.
- The acquisition was recorded with $23.79 million of goodwill and $3.73 million of acquired identifiable intangible assets. The company planned to test goodwill for impairment in the second half of 2019.
- Operating expenses increased, reflecting acquisition and integration costs, expanded payroll and facilities, stock-based compensation, amortization, and a reserve against the CytoBioscience receivable.
- Stock-based compensation was $1.64 million for the first half, versus $460,368 in 2018. Common shares outstanding rose to 30,974,761 at June 30 from 14,091,748 at year-end, with further potential dilution from preferred stock, options, and warrants.
Outlook, risks, and unusual items
- The filing gives no quantified revenue or earnings guidance. Management anticipated growth in Helomics services, citing contracts signed in the third quarter, and said Helomics costs might remain relatively static as revenue grows. These are expectations, not guaranteed results.
- Management said additional financing is necessary to fund operations and debt obligations. Financing may be unavailable or dilutive; without adequate funding, the company may have to curtail business activities. The company also noted that operating needs could increase as it develops Helomics and other businesses.
- In July 2019, the company reduced Skyline Medical staff by ten, including seven sales managers; it recorded $300,673 in severance. A portion is payable over 12 months.
- The company reported a material weakness in internal control over financial reporting: accounting resources lacked sufficient GAAP expertise for complex transactions. Disclosure controls were deemed ineffective as of June 30, 2019; management described plans to reassess staffing and training.
- Nasdaq had granted the company until November 11, 2019, to regain compliance with the $1.00 minimum bid-price requirement, with a reverse stock split identified as a possible remedy.
- Other material risks include Helomics integration and commercialization, reimbursement and regulatory uncertainty for diagnostic testing, competition, intellectual-property protection, and potential impairment of goodwill or other acquired assets. The filing reported no legal proceedings.
Important facts for investors to verify
- Confirm current cash, subsequent financing proceeds, and the company’s ability to meet the September 2019 and February 2020 debt maturities.
- Review the terms, conversion and redemption provisions, and potential dilution from Series E and Series D preferred stock, warrants, options, and convertible debt.
- Assess Helomics’ post-acquisition revenue, cash burn, contract pipeline, integration progress, and the assumptions supporting the $23.79 million goodwill balance.
- Track STREAMWAY unit sales, revenue trends, and whether gross margins improve as management expected.
- Check progress in remediating the material weakness and the company’s Nasdaq bid-price compliance. The filing reports cash of $69,557 on the balance sheet but cites $69,718 in a risk-factor discussion; verify the correct figure.